EN | UA
EN | UA

Help Support

Back

Elagolix improves health-related quality of life in women with endometriosis-related pain

Elagolix improves health-related quality of life in women with endometriosis-related pain Elagolix improves health-related quality of life in women with endometriosis-related pain
Elagolix improves health-related quality of life in women with endometriosis-related pain Elagolix improves health-related quality of life in women with endometriosis-related pain

What's new?

Obstetricians can suggest Elagolix for improving physical, mental, emotional, and social wellbeing in women with endometriosis-related pain/dysmenorrhea.

According to a study in Obstetrics & Gynecology journal, the women who used elagolix for the treatment of pain concerning endometriosis had clinically significant health-related quality of life (HRQOL) improvements.

This study assessed the effects of elagolix on health-related quality of life (HRQOL) evaluated with the help of EHP-30 (Endometriosis Health Profile-30).

The study population who used elagolix for moderate to severe pain relief due to endometriosis was divided into 3 groups as: placebo, elagolix 150 mg once a day, or elagolix 200 mg twice a day. At the starting, the patients were given the EHP-30 questionnaire, and at months 1, 3, and 6 of therapy. Earlier recognized responder definitions were used to decide the proportion of patients with clinically meaningful EHP-30 parameters.

At month 6, the likelihoods of achieving EHP-30 subscale responder definitions for pain, control and powerlessness, self-image, social support, and emotional well-being were 169%, 129%, 80%, 70%, and 67% more, correspondingly, in the 200-mg group, as compared to with placebo. 

The 150-mg group also had higher likelihoods of achieving responder definitions as compared to placebo for all subscales but with lower magnitude than the 200-mg dose of elagolix. Details mentioned in the following table 1:


Table 1: Increased probability of fulfilling the pain subscale responder definition at month 6 for 200 mg and 150 mg doses of elagolix

Source:

Obstetrics & Gynecology

Article:

Health-Related Quality of Life Improvements in Patients with Endometriosis Treated with Elagolix

Authors:

Hugh S. Taylor et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: